Condition: Transthyretin Amyloid Cardiomyopathy · Sponsor: Bayer
Transthyretin (TTR) is a protein made by the liver that helps transport thyroid hormone and vitamin A in the blood. In some people, this protein breaks down and forms harmful clumps called amyloid. TTR amyloid gets deposited in the heart wall and stops it from pumping blood properly, which may lead to heart failure. The breakage in TTR protein can be age-related (wild-type ATTR-CM), or genetic (variant ATTR-CM). The study drug, acoramidis, works by attaching itself to the TTR protein, making TTR more stable and less likely to break down and form amyloid (clumps). This helps to slow down the progression of the disease, improve heart function, and increase the TTR levels in the blood. Acoramidis is an approved treatment for wild-type or variant ATTR-CM in Europe and the United States. Tafamidis is another drug that stabilizes TTR and prevents it from breaking down. In this study, acoramidis will be studied in participants with ATTR--CM who were previously treated with tafamidis. The main purpose of this study is to assess the change in blood TTR levels after participants are switched from tafamidis to acoramidis. This will be studied to understand if acoramidis causes an increase in blood TTR levels beyond the levels achieved with tafamidis. For this, the researchers will measure the change in the levels of TTR protein in participants' blood after 6 months of the treatment with acoramidis, or earlier if a participant stops the treatment before reaching that six-month mark. …
This description comes directly from the study's public registry record.
Bayer Clinical Trials Contact · (+)1-888-84 22937 · clinical-trials-contact@bayer.com
Always discuss trial participation with your own doctor first.
| Universitätsklinikum St. Pölten - Lilienfeld - Klinische Abteilung für Innere Medizin 3 | Sankt Pölten, Lower Austria, Austria | Withdrawn |
| Medizinische Universität Wien- Universitätsklinik für Innere Medizin II, Klinische Abteilung für Kardiologie | Vienna, State of Vienna, Austria | Recruiting |
| Klinik Favoriten - 5.Medizinische Abteilung-Kardiologie | Vienna, State of Vienna, Austria | Not Yet Recruiting |
| Klinik Ottakring - 3. Medizinische Abteilung mit Kardiologie, internistischer Intensivmedizin und Ambulanz | Vienna, State of Vienna, Austria | Not Yet Recruiting |
| Medizinische Universität Graz- Klinische Abteilung für Kardiologie | Vienna, Styria, Austria | Recruiting |
| Krankenhaus St. Josef Braunau | Innere Medizin I | Braunau am Inn, Upper Austria, Austria | Not Yet Recruiting |
| VIVIT - Landeskrankenhaus Feldkirch - Innere Medizin I, Kardiologie, Angiologie, Endokrinologie, Diabetologie, Intensivmedizin | Feldkirch, Vorarlberg, Austria | Withdrawn |
| Hôpital Erasme/Erasmus Ziekenhuis | Brussels, Brussels Capital, Belgium | Not Yet Recruiting |
| AZ St-Jan Brugge-Oostende A.V. | Bruges, West Flanders, Belgium | Not Yet Recruiting |
| KVZ Kardiovaskulaeres Zentrum Darmstadt GmbH | Darmstadt, Hesse, Germany | Not Yet Recruiting |
| Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII - Cardiologia 1 | Bergamo, Italy | Recruiting |
| Azienda Ospedaliero-Universitaria Di Bologna IRCCS_Policlinico Sant'Orsola_Cardiologia | Bologna, Italy | Not Yet Recruiting |
+ 8 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07298044